Leiomyosarcoma of the stomach: Determinants of long-term survival

Gianrico Farrugia, C. H. Kim, C. S. Grant, A. R. Zinsmeister

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

To determine factors associated with a favorable long-term prognosis in gastric leiomyosarcoma, we retrospectively reviewed the medical records of 93 Mayo Clinic patients with this biopsy-proven tumor diagnosed during the 25- year period from 1964 through 1988. Six patients who had Carney's triad (gastric epithelioid leiomyosarcoma, pulmonary chondroma, and functioning extra-adrenal paraganglioma) were excluded from data analysis. The other 87 patients participated in follow-up until death or for a median duration of 5.8 years for those who were alive at the conclusion of the study. The most common symptoms at the time of initial assessment were abdominal pain (51%), melena (36%), and weight loss (16%). Most often, the tumor was located in the greater curvature (25%), fundus (20%), or lesser curvature (16%) of the stomach. Two percent of patients had tumors at multiple sites. All 87 gastric leiomyosarcomas were histologically confirmed; 38% were grade 1, 37% were grade 2, and 25% were either grade 3 or grade 4. Metastatic involvement was noted in 15% of patients at the time of diagnosis. The 5- and 10-year survival rates were 45% and 34%, respectively, and the 5- and 10-year tumor recurrence rates were 57% and 65%, respectively. Variables that were associated with long-term survival were low histologic grade of the tumor, absence of metastatic lesions, and small tumor size (P<0.01); variables such as site of the tumor, initial symptoms, age, and sex provided no significant additional prognostic information.

Original languageEnglish (US)
Pages (from-to)533-536
Number of pages4
JournalMayo Clinic Proceedings
Volume67
Issue number6
StatePublished - 1992

Fingerprint

Leiomyosarcoma
Stomach
Survival
Neoplasms
Extra-Adrenal Paraganglioma
Chondroma
Melena
Abdominal Pain
Medical Records
Weight Loss
Survival Rate
Biopsy
Recurrence
Lung

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Farrugia, G., Kim, C. H., Grant, C. S., & Zinsmeister, A. R. (1992). Leiomyosarcoma of the stomach: Determinants of long-term survival. Mayo Clinic Proceedings, 67(6), 533-536.

Leiomyosarcoma of the stomach : Determinants of long-term survival. / Farrugia, Gianrico; Kim, C. H.; Grant, C. S.; Zinsmeister, A. R.

In: Mayo Clinic Proceedings, Vol. 67, No. 6, 1992, p. 533-536.

Research output: Contribution to journalArticle

Farrugia, G, Kim, CH, Grant, CS & Zinsmeister, AR 1992, 'Leiomyosarcoma of the stomach: Determinants of long-term survival', Mayo Clinic Proceedings, vol. 67, no. 6, pp. 533-536.
Farrugia, Gianrico ; Kim, C. H. ; Grant, C. S. ; Zinsmeister, A. R. / Leiomyosarcoma of the stomach : Determinants of long-term survival. In: Mayo Clinic Proceedings. 1992 ; Vol. 67, No. 6. pp. 533-536.
@article{d38b36f8a7054a0eae6db026db92fa23,
title = "Leiomyosarcoma of the stomach: Determinants of long-term survival",
abstract = "To determine factors associated with a favorable long-term prognosis in gastric leiomyosarcoma, we retrospectively reviewed the medical records of 93 Mayo Clinic patients with this biopsy-proven tumor diagnosed during the 25- year period from 1964 through 1988. Six patients who had Carney's triad (gastric epithelioid leiomyosarcoma, pulmonary chondroma, and functioning extra-adrenal paraganglioma) were excluded from data analysis. The other 87 patients participated in follow-up until death or for a median duration of 5.8 years for those who were alive at the conclusion of the study. The most common symptoms at the time of initial assessment were abdominal pain (51{\%}), melena (36{\%}), and weight loss (16{\%}). Most often, the tumor was located in the greater curvature (25{\%}), fundus (20{\%}), or lesser curvature (16{\%}) of the stomach. Two percent of patients had tumors at multiple sites. All 87 gastric leiomyosarcomas were histologically confirmed; 38{\%} were grade 1, 37{\%} were grade 2, and 25{\%} were either grade 3 or grade 4. Metastatic involvement was noted in 15{\%} of patients at the time of diagnosis. The 5- and 10-year survival rates were 45{\%} and 34{\%}, respectively, and the 5- and 10-year tumor recurrence rates were 57{\%} and 65{\%}, respectively. Variables that were associated with long-term survival were low histologic grade of the tumor, absence of metastatic lesions, and small tumor size (P<0.01); variables such as site of the tumor, initial symptoms, age, and sex provided no significant additional prognostic information.",
author = "Gianrico Farrugia and Kim, {C. H.} and Grant, {C. S.} and Zinsmeister, {A. R.}",
year = "1992",
language = "English (US)",
volume = "67",
pages = "533--536",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "6",

}

TY - JOUR

T1 - Leiomyosarcoma of the stomach

T2 - Determinants of long-term survival

AU - Farrugia, Gianrico

AU - Kim, C. H.

AU - Grant, C. S.

AU - Zinsmeister, A. R.

PY - 1992

Y1 - 1992

N2 - To determine factors associated with a favorable long-term prognosis in gastric leiomyosarcoma, we retrospectively reviewed the medical records of 93 Mayo Clinic patients with this biopsy-proven tumor diagnosed during the 25- year period from 1964 through 1988. Six patients who had Carney's triad (gastric epithelioid leiomyosarcoma, pulmonary chondroma, and functioning extra-adrenal paraganglioma) were excluded from data analysis. The other 87 patients participated in follow-up until death or for a median duration of 5.8 years for those who were alive at the conclusion of the study. The most common symptoms at the time of initial assessment were abdominal pain (51%), melena (36%), and weight loss (16%). Most often, the tumor was located in the greater curvature (25%), fundus (20%), or lesser curvature (16%) of the stomach. Two percent of patients had tumors at multiple sites. All 87 gastric leiomyosarcomas were histologically confirmed; 38% were grade 1, 37% were grade 2, and 25% were either grade 3 or grade 4. Metastatic involvement was noted in 15% of patients at the time of diagnosis. The 5- and 10-year survival rates were 45% and 34%, respectively, and the 5- and 10-year tumor recurrence rates were 57% and 65%, respectively. Variables that were associated with long-term survival were low histologic grade of the tumor, absence of metastatic lesions, and small tumor size (P<0.01); variables such as site of the tumor, initial symptoms, age, and sex provided no significant additional prognostic information.

AB - To determine factors associated with a favorable long-term prognosis in gastric leiomyosarcoma, we retrospectively reviewed the medical records of 93 Mayo Clinic patients with this biopsy-proven tumor diagnosed during the 25- year period from 1964 through 1988. Six patients who had Carney's triad (gastric epithelioid leiomyosarcoma, pulmonary chondroma, and functioning extra-adrenal paraganglioma) were excluded from data analysis. The other 87 patients participated in follow-up until death or for a median duration of 5.8 years for those who were alive at the conclusion of the study. The most common symptoms at the time of initial assessment were abdominal pain (51%), melena (36%), and weight loss (16%). Most often, the tumor was located in the greater curvature (25%), fundus (20%), or lesser curvature (16%) of the stomach. Two percent of patients had tumors at multiple sites. All 87 gastric leiomyosarcomas were histologically confirmed; 38% were grade 1, 37% were grade 2, and 25% were either grade 3 or grade 4. Metastatic involvement was noted in 15% of patients at the time of diagnosis. The 5- and 10-year survival rates were 45% and 34%, respectively, and the 5- and 10-year tumor recurrence rates were 57% and 65%, respectively. Variables that were associated with long-term survival were low histologic grade of the tumor, absence of metastatic lesions, and small tumor size (P<0.01); variables such as site of the tumor, initial symptoms, age, and sex provided no significant additional prognostic information.

UR - http://www.scopus.com/inward/record.url?scp=0026721226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026721226&partnerID=8YFLogxK

M3 - Article

C2 - 1434880

AN - SCOPUS:0026721226

VL - 67

SP - 533

EP - 536

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 6

ER -